Ardelyx Triumphs in FDA Approval for Kidney-Disease Treatment

Ardelyx has received FDA approval for its treatment, Xphozah, designed to control serum phosphorus in patients with chronic kidney disease on dialysis. The approval comes after the drug's previous rejection in July 2021. Xphozah, which requires only two small pills a day, will be available in November as an add-on therapy for patients who cannot tolerate or have an inadequate response to phosphate binders. Ardelyx will present updated data on Xphozah at an American Society of Nephrology meeting in early November.